Trump touts drug-pricing pacts with these 9 pharma manufacturers

President Donald Trump on Aug. 31 announced deals with another nine pharmaceutical manufacturers, bringing to 26 the total number of pricing deals he said will lower U.S. drug prices to levels paid by other nations.

The Trump administration said Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB signed voluntary pacts to lower drug prices. With the deals in place, the Trump administration said it has negotiated deals to lower prices of 89% of brand name drugs.

The nine drugmakers have agreed to sell drugs to state Medicaid programs at "most favored nation" prices that are on par with what other nations pay for the same medications. The manufacturers make drugs that target conditions such as glaucoma, hemophilia, liver disease, macular degeneration, Parkinson’s disease, skin conditions and some types of cancer.

Over the past 11 months, Trump has announced deals with another 17 drug manufacturers that it sent letters to in 2025 seeking price concessions on brand-name drugs. Trump announced the first most favored nation deal with Pfizer on Sept. 30, 2025, and deals trickled in over the following months until April when Regeneron reached a deal with the Trump administration.

While Trump has…

Original source: https://www.usatoday.com/money/